Why it is still important that countries know the burden of pneumococcal disease

Human Vaccines

Volumn 6, Issue 11, 2010, Pages 918-921

  Prato, Rosa ^a   Tafuri, Silvio ^b   Fortunato, Francesca ^a   Martinelli, Domenico ^a  

^a UNIVERSITY OF FOGGIA   (Italy)

^b UNIVERSITY OF BARI   (Italy)

Author keywords

10 Valent pneumococcal conjugate vaccine; 13 Valent pneumococcal conjugate vaccine; 23 Valent pneumococcal polysaccharide vaccine; 7 Valent conjugate vaccine; Invasive pneumococcal disease

Indexed keywords

PNEUMOCOCCUS VACCINE;

DRUG RESEARCH; HUMAN; IMMUNIZATION; INDUSTRIALIZATION; MORTALITY; NOTE; PNEUMOCOCCAL INFECTION; PUBLIC HEALTH SERVICE; VACCINE PRODUCTION;

BACTERIAL TYPING TECHNIQUES; HUMANS; INCIDENCE; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; PREVALENCE; SEROTYPING; STREPTOCOCCUS PNEUMONIAE; VACCINATION;

EID: 78649336856     PISSN: 15548600     EISSN: 15548619     Source Type: Journal    
DOI: 10.4161/hv.6.11.13352     Document Type: Note

References (34)

1. nd printing, Washington DC: Public Health Foundation 2008.
2. World Health Organization. Weekly epidemiological record N 12 2007; 82:93-104; (http://www.who.int/wer).
3. Jacobs MR. Streptococcus pneumoniae: epidemiology and patterns of resistance. Am J Med 2004; 117:3-15.
4. Lynch JP, 3rd, Zhanel GG. Streptococcus pneumoniae: does antimicrobial resistance matter? Semin Respir Crit Care Med 2009; 30:210-38.
5. Lynch JP, 3rd, Zhanel GG. Streptococcus pneumoniae: epidemiology and risk factors, evolution of antimicrobial resistance and impact of vaccines. Curr Opin Pulm Med 2010; 16:217-25.
6. World Health Organization. Weekly epidemiological record N 42 2008; 83:373-84; (http://www.who.int/wer).
7. O'Brien KL, Wolfson LJ, Watt JP, Henkle E, Deloria- Knoll M, McCall N, et al. Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet 2009; 374:893-902.
8. Pebody RG, Hellenbrand W, D'Ancona F, Ruutu P. Pneumococcal disease surveillance in Europe. Euro Surveill 2006; 11:2-646; (http://www. eurosurveillance. org/ViewArticle.aspx?ArticleId = 646).
9. Evers SM, Ament AJ, Colombo GL, Konradsen HB, Reinert RR, Sauerland D, et al. Cost-effectiveness of pneumococcal vaccination for prevention of invasive pneumococcal disease in the elderly: an update for 10 western European countries. Eur J Clin Microbiol Infect Dis 2007; 26:531-40. (Pubitemid 47106804)
10. Isaacman DJ, McIntosh ED, Reinert RR. Burden of invasive pneumococcal disease and serotype distribution among Streptococcus pneumoniae isolates in young children in Europe: impact of the 7-valent pneumococcal conjugate vaccine and considerations for future conjugate vaccines. Int J Infect Dis 2010; 14:197-209.
11. Klugman KP, Madhi SA, Feldman C. HIV and pneumococcal disease. Curr Opin Infect Dis 2007; 20:11-5.
12. Centers for Disease Control and Prevention. Preventing pneumococcal disease among infants and young children: (4) recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2000; 49:1-35.
13. Hofmann J, Cetron MS, Farley MM, Baughman WS, Facklam RR, Elliott JA, et al. The prevalence of drug-resistant Streptococcus pneumoniae in Atlanta. N Engl J Med 1995; 333:481-6.
14. Butler JC, Hofmann J, Cetron MS, Elliott JA, Facklam RR, Breiman RF. The continued emergence of drug-resistant Streptococcus pneumoniae in the United States: an update from the Centers for Disease Control and Prevention's Pneumococcal Sentinel Surveillance System. J Infect Dis 1996; 174:986-93.
15. Moberley S, Holden J, Tatham DP, Andrews RM. Vaccines for preventing pneumococcal infection in adults. Cochrane Database of Systematic Reviews 2008; 422.
16. Pebody RG, Leino T, Nohynek H, Hellenbrand W, Salmaso S, Ruutu P. Pneumococcal vaccination policy in Europe. Euro Surveill 2005; 10:174-8.
17. Assendelf WJ, Scholten RJ, Offringa M. Pneumococcal vaccination for the elderly in The Netherlands? Assessment of the quality and content of available comparative studies. Neth J Med 2004; 62:36-44. (Pubitemid 39089455)
18. Cornu C, Yzebe D, Leophonte P, Gaillat J, Boissel JP, Cucherat M. Efficacy of pneumococcal polysaccharide vaccine in immunocompetent adults: a meta-analysis of randomized trials. Vaccine 2001; 19:4780-90.
19. Fine MJ, Smith MA, Carson CA, Meffe F, Sankey SS, Weissfeld LA, et al. Efficacy of pneumococcal vaccination in adults. A meta-analysis of randomized controlled trials. Arch Intern Med 1994; 154:2666-77.
20. Hutchison BG, Oxman AD, Shannon HS, Lloyd S, Altmayer CA, Thomas K. Clinical effectiveness of pneumococcal vaccine. Meta-analysis. Can Fam Physician 1999; 45:2381-93.
21. Moore RA, Wiffen PJ, Lipsky BA. Are the pneumococcal polysaccharide vaccines effective? Metaanalysis of the prospective trials. BMC Fam Pract 2000; 1:1.
22. Watson L, Wilson BJ, Waugh N. Pneumococcal polysaccharide vaccine: a systematic review of clinical effectiveness in adults. Vaccine 2002; 20:2166-73.
23. Reinert RR, Paradiso P, Fritzell B. Advances in pneumococcal vaccines: the 13-valent pneumococcal conjugate vaccine received market authorization in Europe. Expert Rev Vaccines 2010; 9:229-36.
24. Pneumococcal vaccines accelerated development and introduction plan 1. (pneumoADIP). (http://www.preventpneumo.org).
25. De Carvalho Gomes H, Muscat M, Monnet DL, Giesecke J, Lopalco PL. Use of seven-valent pneumococcal conjugate vaccine (PCV7) in Europe 2001-2007. Euro Surveill 2009; 14:2-19159; (http://www.eurosurveillance.org/ViewArticle.aspx? ArticleId=19159).
26. Centers for Disease Control and Prevention. Progress in introduction of pneumococcal conjugate vaccine - worldwide 2000-2008. MMWR Morb Mortal Wkly Rep 2008; 57:1148-51.
27. Dinleyici EC, Yargic ZA. Pneumococcal conjugated vaccine: PHiD-CV. Expert Rev Anti Infect Ther 2009; 7:1063-74.
28. Vesikari T, Karvonen A, Lindblad N, Korhonen T, Lommel P, Willems P, et al. Safety and immunogenicity of a booster dose of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine coadministered with measlesmumps- rubella-varicella vaccine in children aged 12 to 16 months. Pediatr Infect Dis J 2010; 29:47-56.
29. Pilishvili T, Lexau C, Farley MM, Hadler J, Harrison LH, Bennett NM, et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis 2010; 201:32-41.
30. Centers for Disease Control and Prevention. Invasive pneumococcal disease in children 5 years after conjugate vaccine introduction - eight states 1998-2005. MMWR Morb Mortal Wkly Rep 2008; 57:144-8.
31. Centers for Disease Control and Prevention. Licensure of a 13-valent pneumococcal conjugate vaccine (PCV13) and recommendations for use among children - Advisory Committee on Immunization Practices (ACIP) 2010. MMWR Morb Mortal Wkly Rep 2010; 59:258-61.
32. Bryant KA, Block SL, Baker SA, Gruber WC, Scott DA. PCV13 Infant Study Group. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine. Pediatrics 2010; 125:866-75.
33. Centers for Disease Control and Prevention. Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease - United States 1998-2003. MMWR Morb Mortal Wkly Rep 2005; 54:893-7.
34. Centers for Disease Control and Prevention. Invasive pneumococcal disease in young children before licensure of 13-valent pneumococcal conjugate vaccine - United States 2007. MMWR Morb Mortal Wkly Rep 2010; 59:253-7.